In response to the SARS‑CoV‑2 outbreak, and the resulting COVID‑19 pandemic, a global
competition to develop an anti‑COVID‑19 vaccine has ensued. The targeted time frame for …

Rapid development of an efficacious vaccine against the viral pathogen severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease …

Introduction A novel strain of coronavirus, SARS-CoV-2, has triggered a global pandemic of
coronavirus disease (COVID-19) in late 2019. In January 2020, the WHO declared this …

Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …

The development of safe and effective vaccines has been an overriding priority for
controlling the 2019-coronavirus disease (COVID-19) pandemic. From the onset, COVID-19 …

SARS‐CoV‐2 is the novel coronavirus behind the COVID‐19 pandemic. Since its
emergence, the global scientific community has mobilized to study this virus, and an …

A few centuries ago, the first vaccine vial was formulated, and since then, they have resulted
in an eminent reduction in infectious diseases associated morbidity and mortality. The …

Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in
Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an urgent …

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …